Overview

Gender

male

Dr. Roger Tung is the scientific founder, President, and CEO of Concert Pharmaceuticals, which he co-founded in 2006.

Before Concert, Roger worked in venture-backed start-up and major pharmaceutical companies; including Vertex Pharmaceuticals, as a founding scientist and most recently Vice President of Drug Discovery; Merck; and E.R. Squibb & Sons.

At Vertex, he co-invented the marketed HIV protease inhibitors Lexiva® and Agenerase®, and oversaw the discovery of Incivek® and Kalydeco®, approved respectively to treat HCV infection and cystic fibrosis caused by the G551D CFTR mutation. Roger has published widely and been granted 60 U.S. patents.

He received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison from Professor Daniel H. Rich.

Roger is a scientific advisor to public and private biotech companies and serves on the Board of Visitors of the University of Wisconsin-Madison School of Pharmacy.